Avacta Group PLC Director Appointment (2035O)
January 28 2019 - 2:00AM
UK Regulatory
TIDMAVCT
RNS Number : 2035O
Avacta Group PLC
28 January 2019
28 January 2019
Avacta Group plc
("Avacta", the "Group" or the "Company")
Director Appointment
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and reagents, is pleased to announce the
appointment of Dr Sam Williams as Non-Executive Director to the
Board with immediate effect.
Dr Williams is currently Managing Partner and Head of Life
Sciences at IP Group plc, the FTSE 250 investor in Life Sciences
and Technology. He has an outstanding track-record in the biotech
sector, both as a top-ranked biotechnology analyst in the City
whilst at Lehman Brothers and, subsequently, as a Director and CEO,
in which capacity he has overseen the development of novel
therapeutics through early-stage clinical testing and successfully
negotiated global alliances with major pharmaceutical companies.
Thus, he brings extensive financial, operational and investment
expertise to the Avacta Board.
Dr Williams was awarded a PhD in Molecular Biology by Cambridge
University, earned while working in the laboratory of Sir Greg
Winter, Nobel Laureate, and has a degree in Biology from Oxford
University.
Dr Eliot Forster, Chairman of Avacta Group, commented:
"I am delighted that Dr Williams is joining Avacta and very much
look forward to working with him. Sam has extensive experience of
the Biotech industry both as an investor and operator which he will
bring to the Board."
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0) 844 414 0452
Alastair Smith, Chief Executive www.avacta.com
Officer
Tony Gardiner, Chief Financial Officer
finnCap Ltd Tel: +44 (0) 207 220 0500
Geoff Nash / Giles Rolls - Nominated www.finncap.com
Adviser
Tim Redfern - ECM
Tel: +44 (0) 203 705 9318
WG Partners Tel: +44 (0) 203 705 9217
Nigel Birks / Nigel Barnes www.wgpartners.co.uk
David Wilson / Claes Spang
Turner Pope Investments Tel: 020 3621 4120
James Pope www.turnerpope.com
Ben Turner
Zyme Communications (Trade and Regional Tel: +44 (0)7787 502 947
Media) katie.odgaard@zymecommunications.com
Katie Odgaard
Yellow Jersey (Financial Media and Tel: +44 (0)7764 947137
IR) Tel: +44 (0)7544 275882
Sarah Hollins avacta@yellowjerseypr.com
Harriet Jackson
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite
their shortcomings. Affimer(R) technology has been designed to
address many of these negative performance issues, principally; the
time taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer(R) technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an
in-house focus on immuno-oncology as well as partnered development
programmes. Avacta is commercialising non-therapeutic Affimer(R)
reagents through licensing to developers of life sciences research
tools and diagnostics.
Regulatory disclosure - The following information is disclosed
in accordance with Rule 17 and paragraph (g) of Schedule 2 of the
AIM Rules for Companies.
Samuel Cameron Williams, 49, holds 19,537 ordinary shares in the
Company. Dr. Williams' current and previous directorships are as
follows:
Current Directorships/Partnerships:
18 Arundel Gardens Management Limited
Diurnal Group Plc
Genomics Plc
Iksuda Therapeutics Limited
Istesso Limited
Modern Biosciences Nominees Limited
MBS Director Limited
MBS Secretarial Limited
MBS4 Limited
MBS3 Limited
MBS5 Limited
Modern Biosciences Limited
PIMCO 2664 Limited
Directorships/Partnerships held in last 5 years:
Bioindustry Association
C4X Discovery Holdings plc
C4X Discovery Limited
C4X Drug Discovery Limited
Diurnal Limited
Karus Therapeutics Limited
Save for the disclosures above, there are no further disclosures
to be made in accordance with Rule 17 and Schedule 2(g) of the AIM
Rules.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOADGGDBCGDBGCR
(END) Dow Jones Newswires
January 28, 2019 02:00 ET (07:00 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024